1154061-26-3Relevant academic research and scientific papers
RAD51 INHIBITORS
-
Page/Page column 139-140, (2020/09/27)
This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065
-
Page/Page column 77-78, (2009/05/28)
The invention provides compounds of formula wherein R1, R2, R3, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1
BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066
-
Page/Page column 169, (2009/06/27)
The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
